INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

Core Insights - INmune Bio, Inc. (NASDAQ: INMB) reported Q1 2025 business and financial results on May 8th, 2025, surpassing analyst estimates [1] - The company is on track to share results of its ongoing projects, indicating progress in its research and development efforts [1] Financial Performance - The financial results for Q1 2025 showed a positive trend, with the company beating analyst expectations [1] Research and Development - INmune Bio focuses on novel Cell & Gene Therapies (CGT) aimed at addressing various clinical needs, showcasing its commitment to innovation in the biotechnology sector [1]